KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $66.3 million.

  • Nektar Therapeutics' Total Current Liabilities fell 1.84% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year decrease of 1.84%. This contributed to the annual value of $61.4 million for FY2024, which is 19.76% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Total Current Liabilities stood at $66.3 million, which was down 7.08% from $71.4 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Total Current Liabilities high stood at $140.0 million for Q3 2021, and its period low was $50.7 million during Q2 2023.
  • Over the past 3 years, Nektar Therapeutics' median Total Current Liabilities value was $59.9 million (recorded in 2023), while the average stood at $60.1 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 67.25% in 2021, then surged by 35.35% in 2025.
  • Nektar Therapeutics' Total Current Liabilities (Quarterly) stood at $85.2 million in 2021, then fell by 19.95% to $68.2 million in 2022, then declined by 24.83% to $51.3 million in 2023, then rose by 19.76% to $61.4 million in 2024, then declined by 1.84% to $66.3 million in 2025.
  • Its Total Current Liabilities was $66.3 million in Q3 2025, compared to $71.4 million in Q2 2025 and $70.9 million in Q1 2025.